Filing Flows › Biogen (BIIB) › Guidance & outlook
Biogen (BIIB) guidance and outlook
Biogen (BIIB) raised its guidance on Oct 28, 2026: EPS $12.20–$13.00 for FY2026. Biogen's 10-Q filed Jul 29, 2026 makes 38 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | FY2026 | $12.20–$13.00 | raised |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Jul 29, 2026
- We believe that the Solothurn facility will support our anticipated near to mid-term needs for the manufacturing of biologic assets.
- If we are unable to fully utilize our manufacturing facilities, we will incur additional excess capacity charges which would have a negative effect on our financial condition and results of operations.
- We expect the future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar.
- The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue compared to prior periods, and we expect that TECFIDERA revenue will continue to decline.
- We are working to mitigate potential exposure from tariffs across our network, and as of the date of this filing, we do not expect the tariffs currently applicable to our business to result in a material adverse effect on our operations in 2026.
- We will continue to monitor the current and future global tariff landscape as it evolves.
- Government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved.
- We will continue to evaluate and take actions to mitigate any potential impacts on our business, results of operations and financial condition.
- We will continue to monitor the ongoing conflict between Russia and Ukraine as well as the military conflict in the Middle East and other global geopolitical developments and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations.
- We expect drug pricing and other healthcare costs will continue to be subject to political and societal pressures on a global basis.
- As the policy environment remains dynamic, we will continue to monitor how uncertainty with respect to how the U.S. and foreign tariffs and the U.S. and international pricing may impact our business in the future.
- Preliminary guidance has been issued by the IRS and we expect additional guidance and regulations to be issued in future periods.
Biogen's latest quarter
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
Questions
Did Biogen raise or lower its guidance?
Biogen (BIIB) raised its guidance on Oct 28, 2026: EPS $12.20–$13.00 for FY2026.
What does Biogen expect?
We believe that the Solothurn facility will support our anticipated near to mid-term needs for the manufacturing of biologic assets. If we are unable to fully utilize our manufacturing facilities, we will incur additional excess capacity charges which would have a negative effect on our financial condition and results of operations. We expect the future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.